UDG Healthcare plc announced the acquisition of Cambridge BioMarketing LLC, a U.S.-based healthcare communications business, for a total consideration of up to $35 million.
Fingerpaint, a full-service marketing agency with offices in Arizona, Pennsylvania, New York and Ohio, named a longtime creative duo as the new leaders of the agency’s creative team. Katie Beller and Andy Spitzer will be based in the agency’s headquarters in Saratoga Springs, New York.
For the first time, EPGL reveals the “Omega” contact lens under development with InWith Corp. The patent pending “Omega” is designed to correct vision anytime by changing the curvature of the lenses on-demand, via smart phone or other mobile devices.
The National Pharmaceutical Council will host a webinar, “Same Condition, Different Costs: Should Patients Pay Different Amounts?” to discuss the practical realities of different cost-sharing models for prescription drugs.
From the leaders of marketing teams to medical affairs, pharma executives are increasingly required to do more with less. While this is true across industries, the U.S. biopharma industry is faced with unique headwinds.
From the latest in VR to imaginative Social Engagement approaches, here are Ben Putman’s Top Five Digital Marketing takeaways for 2017.
A recent article in the New York Times, headlined Netflix Lets Viewers Pick the Plot, tells how the video streaming behemoth is creating content with an interactive twist.
Pfizer Inc. announced that the supplemental New Drug Application for Xeljanz (tofacitinib citrate), an investigational oral treatment for adult patients with moderately to severely active ulcerative colitis, has been accepted for filing by the U.S. Food and Drug Administration.
Novo Nordisk and Glooko announced that the new Cornerstones4Care Powered by Glooko app (C4C app) is now available to help people more effectively manage their diabetes.
Fueled by a desire for innovation and new medical breakthroughs, the biotech industry continues to enjoy substantial growth due to increased investment in R&D.
